




GROWTH HORMONE AND LIVER FIBROSIS: OLD DOG, NEW TRICKS?

GUEST LECTURE by




Prof. Dr. Emilio Casanova
Ludwig Boltzmann Institute for Cancer Research,
Medical University of Vienna, Austria
Monday, 08.02.2016
17:00


Lecture Hall, Department of Pathology, MUG
(Auenbruggerplatz 15, ground floor)




Severe jaundice and premature lethality in *stat3^{Δhc} mdr2^{-/-}* mice. Mair et al. (2010) *Gastroenterology* 138:2499-508




Bridging fibrosis in *Mdr2^{-/-}* mice upon loss of *STAT5* or *STAT3*. Mair et al. (2011) *Front Biosci (Landmark Ed)*. 16:2794-811




Schematic of *STAT3* and *STAT5* functions in hepatic cell types that are implicated in cholestasis-induced liver fibrosis. Mair et al. (2011) *Front Biosci (Landmark Ed)*. 16:2794-811




Phenotypic effects of hepatic *STAT5* deletion in *Mdr2^{-/-}* mice. Blaas et al. (2010) *Hepatology* 51: 1319-26




Ghr^{-/-}; Mdr2^{-/-} mice develop a severe liver fibrosis phenotype. Stiedl et al. (2015) *Hepatology* 138:613-26



Ghr deletion combined with loss of *Mdr2* increases liver damage. Stiedl et al. (2015) *Hepatology* 138:613-26



Impact of GR agonist or antagonist treatment on WAT lipolysis. Mueller et al. (2011) *Hepatology* 54:1398-409



Deletion of *Ghr* suppresses liver tumorigenesis. Stiedl et al. (2015) *Hepatology* 138:613-26